retatrutide phase 3 trials produces up to 30.3% weight loss in trial Retatrutide just delivered the first
Description
CONCLUSION This review highlights key findings from the current literature on the neuropsychiatric effects of GLP1RAs
This was supported by a recent metanalysis in which, twenty- two randomized controlled trials involving 61,412 patients who were either T2DM patients with or without cardiovascular disease or patients with cardiovascular disease alone, were included in the meta-analysis, and results have shown the diastolic function according to echocardiography was significantly improved by GLP-1R agonists [88]
Exercise matters even more, because the goal is not just weight loss
Understanding how long you might stay on treatment helps set appropriate expectations from the beginning
Athauda D, Gulyani S, Karnati HK, et al
